Here's an example of a P2 cancer drug with positive results

New Post Public Reply Private Reply Replies (0) Message Board
sjacobs26
530
Here's an example of a P2 cancer drug with positive results getting approval.
Quote:
Patients on trastuzumab deruxtecan, also known as DS-8201, who had already undergone roughly six prior treatment courses, were saw no further progression for a median of 16.4 months.

https://www.yahoo.com/news/astrazeneca-daiich...30062.html
Quote:
Trastuzumab deruxtecan was previously granted US FDA Breakthrough Therapy Designation and Fast Track designation. The BLA is based on the combination of data from the Phase I trial published in The Lancet Oncology and the pivotal Phase II DESTINY-Breast01 trial.1 The response rate observed in DESTINY-Breast01, as assessed by an independent review committee, validated the clinical activity observed in the Phase I trial.

Quote:
The Prescription Drug User Fee Act (PDUFA) date for trastuzumab deruxtecan, a HER2-targeting antibody drug conjugate (ADC) and potential new medicine for the treatment of HER2-positive metastatic breast cancer, is set for the second quarter of 2020.

Quote:
DESTINY-Breast01 is a pivotal Phase II, open-label, global, multicentre, two-part trial evaluating the safety and efficacy of trastuzumab deruxtecan in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine. The primary endpoint of the trial is objective response rate, as determined by independent central review. Secondary objectives include duration of response, disease control rate, clinical benefit rate, progression-free survival and overall survival. Enrolment into DESTINY-Breast01 was completed in September 2018 with 253 patients at more than 100 sites across North America, Europe, Japan and other countries in Asia.

The safety and tolerability profile of trastuzumab deruxtecan in DESTINY-Breast01 was consistent with the Phase I trial data published in The Lancet Oncology, in which the most common adverse events (≥30 percent, any grade) included nausea, decreased appetite, vomiting, alopecia, fatigue, anaemia, diarrhoea and constipation. Cases of drug-related interstitial lung disease and pneumonitis, including grade 5 events, have also been reported in the clinical development programme.

https://www.astrazeneca.com/media-centre/pres...02019.html

They enrolled over 250 patients (estimated to be 99 in US) and took time to determine PFS and OS rates (due to no secondary endpoints like CTC).
Quote:
Secondary Outcome Measures :
Duration of Response (DoR) [ Time Frame: within 24 months ]
Disease Control Rate (DCR) [ Time Frame: within 24 months ]
Progression Free Survival (PFS) [ Time Frame: within 24 months ]
PFS is defined as the time from randomization until objective tumor progression or death, whichever occurs first.

Time to Response based on central review [ Time Frame: within 24 months ]
Overall Survival (OS) [ Time Frame: within 24 months ]
Overall survival is defined as the time from randomization until death from any cause and is measured in the intent-to-treat population.

ORR [ Time Frame: within 24 months ]
ORR, as assessed by the investigator based on RECIST Version 1.1.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

191 Schools Honored for Academic Growth Success

Updated Category News Views 65

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
Mastering Prescription Labels: Critical Insights for Safety

Updated Category News Views 27

Revolutionizing How We Approach Prescription Labels Prescription labels aren't just scraps of paper or stickers slapped on bottles; they're lifelines. The insight from pharmacy expert Sheldon Birch could turn a regular label into a powerful tool for health management. According to Birch, the label is often disregarded yet speaks volumes about the medication you've got in...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 59

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 120

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 55

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 109

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 55

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 67

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 142

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 159

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading

Top 5 Most Recently Viewed Articles

Moatable, Inc. Concludes the Tender Offer for Class A Shares

Updated Category News Views 139

Moatable, Inc. Completes Tender Offer for Class A Shares Moatable, Inc. (Pink Limited Market: MTBLY), a premier US-based SaaS company, has announced the successful completion of its fixed price tender offer. The company aimed to repurchase an impressive 225 million Class A ordinary shares. Each share has a par value of $0.001, and they can also be represented by American...

Continue Reading
Armstrong World Industries' Q4 Earnings: What Investors Need

Updated Category News Views 164

Armstrong World Industries Q4 Earnings Report Let’s dive right into this latest earnings report from Armstrong World Indus (NYSE:AWI) that just hit the streets. Released on February 24, 2026, bright and early, it’s got both good news and some not-so-great tidbits that every investor should chew on. Honestly, missing earnings estimates by a margin like -3.59% just...

Continue Reading
Batteries Plus Enhances Partnership for Educational Safety Needs

Updated Category News Views 254

Batteries Plus Enhances Partnership for Educational Safety Needs From Campus Fleets to Classroom Security, Local Teams Support Operational Readiness for Schools and Universities Nationwide Batteries Plus is deepening its partnerships with K-12 districts, colleges, and universities by supplying a broad range of comprehensive battery, lighting, and security system support....

Continue Reading
Exciting Developments in Houston: The RO Project Advances

Updated Category News Views 453

Transwestern Launches Next Phase of The RO Development Transwestern, a prominent commercial real estate firm headquartered in Houston, has taken a monumental step forward by breaking ground on the next phase of The RO. This innovative project aims to redefine the River Oaks neighborhood, representing a significant addition to the area that harmonizes various aspects of...

Continue Reading
BMO Financial Group Plans Large Share Repurchase Initiative

Updated Category News Views 95

BMO Financial Group's Strategic Share Buyback Program Bank of Montreal (TSX:BMO)(NYSE:BMO) has announced an ambitious plan to repurchase up to 20 million common shares through a normal course issuer bid. This initiative is designed to strengthen the bank's capital structure and reflects its confidence in its business fundamentals. Details of the Share Repurchase Plan The...

Continue Reading